A comparison of two chemotherapy regimens for non small cell lung cancer in a medical college

Author: 
Saurabh Karmakar., Jitendra Bhatt., Pradeep Kumar Mukherji., Rajendra Prasad., Surya Kant and Sanjeev Kumar Verma

A study was conducted in Department of Pulmonary Medicine, King George's Medical University, Lucknow to evaluate the efficacy and toxicity of combination therapy of Mitomycin, Ifosfamide, Cisplatin (MIC) and Cisplatin, Etoposide (CE) in the treatment of Non-Small Cell Lung Cancer (NSCLC). The objectives were response rates and evaluation of toxicity. The response rate in MIC group was 75%; no change in disease was observed in 25% (3/12 pts) and partial response in 50% (6/12
pts). The response rate in CE group was 55.6% (5/9 pts); no change in disease was observed in 33.4% (3/9 pts) & partial response in 22.2% (2/9 pts). Mitomycin, ifosfamide, cisplatin was found to be superior combination therapy compared to cisplatin and etoposide.

Download PDF: 
DOI: 
DOI: http://dx.doi.org/10.24327/ijcar.2017.5323.0698